Physician profile
Muhammad Ahsan
NPI 1396725305
$1,218.01
in general payments reported to CMS, 2019-2025
20 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $59.44 · 2021: $128 · 2022: $237 · 2023: $69.56 · 2024: $209 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $306 · Travel and Lodging: $291 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $306.42 |
| Travel and Lodging | $290.86 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $384.91 | 2020-2025 | Proclaim |
| Amgen INC. | $178.26 | 2019-2022 | |
| Medtronic Vascular, INC. | $100.29 | 2019-2020 | |
| Abbvie INC. | $74.69 | 2022 | |
| Janssen Pharmaceuticals, INC | $68.94 | 2023-2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.25 | 2022-2025 | Jardiance |
| Ardelyx, INC. | $50.16 | 2024 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $48.33 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $34.68 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $29.84 | 2021-2024 | Farxiga |
| Daiichi Sankyo INC. | $26.18 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $23.32 | 2023 | Opsumit |
| Shield Therapeutics INC | $23.17 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $22.63 | 2023 | |
| Novo Nordisk INC | $16.25 | 2024 | Wegovy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $15.65 | 2025 | Oxlumo |
| Glaxosmithkline, LLC. | $15.01 | 2021 | |
| Vivus LLC | $14.43 | 2022 | |
| Vivaquant INC, Dba Rhythm Express | $13.60 | 2024 | Rhythm Express |
| Daxor Corporation | $9.42 | 2023 | Bva-100 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ahsan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.